Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.

Abstract

BACKGROUND:

Vinblastine is the standard treatment for children with Langerhans cell histiocytosis (LCH). Whether this treatment could be extended to adults with LCH is questionable. This retrospective multicenter study included 35 adult patients (median age 33 years; 23 men; 80% with multisystem LCH) who were treated with vinblastine + steroids as a first-line chemotherapy and followed for a median time of 83 months. The objectives were to determine the overall response rate (based on the Histiocyte Society criteria), disease reactivation rate, toxicity, permanent consequences, and survival rate corresponding to this treatment. The lung involvement outcome was based on serial lung function tests. The distribution of right-censored end points was estimated by the Kaplan-Meier method. Univariate Cox model with time-fixed and time-varying covariates was used for the predictive analysis of reactivation in the responders. Univariate analyses of risk factors for neurotoxicity were based on nonparametric Wilcoxon rank sum tests and exact Fisher tests.

RESULTS:

The median duration of the first course of vinblastine was 7.6 months, with a median cumulative dose of 160 mg [IQR 120-212]. Seventy percent of the patients were responders at the end of this treatment. Subsequently, LCH reactivation occurred with a 5-year cumulative incidence of 40%. During the study, 27 reactivations were observed in 17 patients, and half of these episodes were retreated with vinblastine. At the end of the last vinblastine treatment, 70% of the patients were responders. None of the patients with impaired lung function improved. No grade 3-4 peripheral neuropathy was observed. At the final vinblastine treatment, permanent LCH consequences, primarily pituitary stalk involvement, were present in 15 (43%) patients, and all were present at the time of vinblastine initiation. The 10-year survival rate was 86.2% (95CI, 71.8-100%), and the 2 patients who died from LCH had risk organ localizations.

CONCLUSIONS:

Vinblastine is an effective and well-tolerated first-line treatment for adult LCH except in patients with lung involvement and impaired lung function. However, a significant portion of patients experienced LCH reactivation during long-term follow up. As in childhood LCH, the presence of risk organ involvement has a negative impact on patient prognosis.

• Authors: Abdellatif Tazi, Gwenaël Lorillon, Julien Haroche, Antoine Neel, Stéphane Dominique, Achille Aouba, Jean-David Bouaziz, Constance de Margerie-Melon, Emmanuelle Bugnet, Vincent Cottin, Thibault Comont, Christian Lavigne, Jean-Emmanuel Kahn, Jean Donadieu, Sylvie Chevret
• Journal: Orphanet journal of rare diseases (Orphanet J Rare Dis) Vol. 12 Issue 1 Pg. 95 (05 22 2017) ISSN: 1750-1172 [Electronic] England
• PMID: 28532436 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents, Phytogenic
• Vinblastine

Topics

• Adult
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Female
• Follow-Up Studies
• Histiocytosis, Langerhans-Cell (diagnosis, drug therapy, mortality)
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Survival Rate (trends)
• Vinblastine (therapeutic use)